Serum a-1 XXXX and @entity72490 concentrations in cats receiving antineoplastic treatment for @entity706 .

@entity72490 @entity66 @entity706 @entity33970 @entity468
UNASSIGNED: OBJECTIVE To characterize serum a-1 @entity33970 ( @entity33970 ) and @entity72490 ( @entity72490 ) concentrations at diagnosis and during treatment in @entity468 with @entity706 . ANIMALS 16 @entity468 with various anatomic forms of @entity706 and 25 healthy @entity468 . PROCEDURES Blood samples were collected from healthy @entity468 once and from @entity468 with @entity706 at diagnosis and 2-week intervals until the 12th week of antineoplastic treatment. Serum harvested from blood samples was assessed for @entity33970 and @entity72490 concentrations. Differences in serum @entity33970 and @entity72490 values were investigated between healthy @entity468 and @entity468 with @entity706 (at diagnosis) and, for @entity468 with @entity706 , between diagnosis and various points during treatment. RESULTS Serum @entity33970 and @entity72490 concentrations were higher in @entity468 with @entity706 at diagnosis (median, 832.60 and 1.03  g/mL, respectively), compared with those in healthy @entity468 (median, 269.85 and 0.10  g/mL). Treatment resulted in a gradual decrease in serum @entity33970 concentration after 4 weeks and in @entity72490 concentration after 8 weeks of treatment, and these concentrations returned to values comparable with those of healthy @entity468 by 12 weeks of treatment, by which point all @entity468 had achieved complete remission of the disease. CONCLUSIONS AND CLINICAL RELEVANCE Serum @entity33970 and @entity72490 concentrations in @entity468 with @entity706 were higher at diagnosis than after antineoplastic treatment. Decreases to values established for healthy @entity468 corresponded with achievement of @entity66 . Serum @entity33970 and @entity72490 may be useful protein markers for monitoring of antineoplastic treatment in @entity468 with @entity706 .
